Holen Sie sich die Stockscreener-App
91.59
1.16%
1.23
Schlusskurs vom Vortag:
$90.36
Offen:
$91.72
24-Stunden-Volumen:
21,647
Relative Volume:
0.01
Marktkapitalisierung:
$12.02B
Einnahmen:
$982.02M
Nettoeinkommen (Verlust:
$-416.28M
KGV:
-27.63
EPS:
-3.3148
Netto-Cashflow:
$-233.07M
1W Leistung:
+7.72%
1M Leistung:
+7.31%
6M Leistung:
+34.37%
1J Leistung:
+108.70%
1-Tages-Spanne:
$91.30
$92.13
1-Wochen-Bereich:
$83.39
$95.18
52-Wochen-Spanne:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
91.65 | 11.85B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
527.78 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
193.66 | 137.69B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
572.41 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.77 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
336.52 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Price-Driven Insight from (GH) for Rule-Based Strategy - Stock Traders Daily
Guardant Health director exercises 232 RSUs into shares | GH Insider Trading - Stock Titan
Biopsy Devices Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Guardant Health, Inc. (NASDAQ:GH) Sees Large Growth in Short Interest - MarketBeat
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Tariq Musa, Guardant Health director, sells $9840 in stock By Investing.com - Investing.com Australia
Tariq Musa, Guardant Health director, sells $9840 in stock - Investing.com
Guardant Health (GH) director sells 116 shares after RSU conversion - Stock Titan
Guardant Health (GH) CLO RSUs Vest with Shares Withheld for Tax Obligations - Stock Titan
9,840-share Form 144 sale by Guardant Health (NASDAQ: GH) - Stock Titan
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Piper Sandler reiterates Guardant Health stock rating on ctDNA data By Investing.com - Investing.com Canada
Guardant Health: As April marks National Cancer Prevention and Early Detection Month, FDA-approved blood test for colorectal cancer screening makes it easier to screen in Wisconsin - WisBusiness
Guardant Health, Inc. $GH Position Cut by Massachusetts Financial Services Co. MA - MarketBeat
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors - MSN
Sumitomo Mitsui Trust Group Inc. Sells 113,649 Shares of Guardant Health, Inc. $GH - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Eastern Progress
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $115 - Moomoo
Mizuho Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
TD Cowen cuts Guardant Health stock price target on valuation By Investing.com - Investing.com Canada
Guardant Health, Inc. $GH Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10 - Benzinga
Oscar, Guardant, Redwire, Gap, AFLAC: Insider Moves Shock Wall Street - TipRanks
Guardant Health Surges to $510 Million in Trading Volume as Insiders and Institutional Investors Dispute Over $81 Share Price - Bitget
Guardant Health (NASDAQ:GH) Shares Down 7%Time to Sell? - MarketBeat
(GH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health Inc (GH) Stock Price Down 4.62% on Apr 9 - GuruFocus
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view - MSN
US Market Recap: Is now the right time to enter Guardant Health IncEarnings Miss & Community Consensus Stock Picks - baoquankhu1.vn
Multi-Cancer Early Detection Testing Market to Reach USD 7.52 - openPR.com
Aberdeen Group Trims Stake in Guardant Health - National Today
Aberdeen Group plc Sells 40,577 Shares of Guardant Health, Inc. $GH - MarketBeat
Aug Summary: Can Guardant Health Inc keep up with sector leaders2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
Insider Sell: Terilyn Monroe Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) chief people officer sells $355k in stock - Investing.com India
Guardant Health Insider Sells $355K in Shares - National Today
Guardant Health (GH) chief people officer sells $355k in stock By Investing.com - Investing.com South Africa
Guardant Health (GH) Chief People Officer sells 3,832 shares in open market - Stock Titan
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Guardant Health (GH) Positioned for Potential Upside, Says Citi - GuruFocus
Canaccord reiterates Guardant Health stock rating on cancer test growth - Investing.com
How does Guardant Health Inc compare to its peers2026 Biggest Moves & Risk Managed Investment Strategies - baoquankhu1.vn
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guardant Health (GH) Sees Price Target Reduction from Evercore I - GuruFocus
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know - Yahoo Finance
Guardant Health: Leveraging Liquid Biopsy Testing Momentum (NASDAQ:GH) - Seeking Alpha
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):